1. Home
  2. VRTX vs ELV Comparison

VRTX vs ELV Comparison

Compare VRTX & ELV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$452.25

Market Cap

96.6B

Sector

Technology

ML Signal

HOLD

Logo Elevance Health Inc.

ELV

Elevance Health Inc.

HOLD

Current Price

$359.71

Market Cap

78.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
ELV
Founded
1989
1944
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.6B
78.9B
IPO Year
1991
N/A

Fundamental Metrics

Financial Performance
Metric
VRTX
ELV
Price
$452.25
$359.71
Analyst Decision
Buy
Buy
Analyst Count
25
16
Target Price
$494.64
$392.47
AVG Volume (30 Days)
1.4M
1.6M
Earning Date
11-03-2025
01-22-2026
Dividend Yield
N/A
1.91%
EPS Growth
N/A
N/A
EPS
14.22
24.39
Revenue
$11,723,300,000.00
$194,820,000,000.00
Revenue This Year
$11.01
$13.17
Revenue Next Year
$8.74
$3.66
P/E Ratio
$31.78
$14.72
Revenue Growth
10.33
11.96
52 Week Low
$362.50
$273.71
52 Week High
$519.68
$458.75

Technical Indicators

Market Signals
Indicator
VRTX
ELV
Relative Strength Index (RSI) 59.92 69.23
Support Level $433.81 $325.29
Resistance Level $463.85 $336.45
Average True Range (ATR) 10.71 9.28
MACD 0.51 3.33
Stochastic Oscillator 72.53 91.45

Price Performance

Historical Comparison
VRTX
ELV

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About ELV Elevance Health Inc.

Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of June 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.

Share on Social Networks: